Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Melanoma genetics and the development of rational therapeutics.

Literature DB >> 15841168

Melanoma genetics and the development of rational therapeutics.

Yakov Chudnovsky¹, Paul A Khavari, Amy E Adams.

Abstract

Melanoma is a cancer of the neural crest-derived cells that provide pigmentation to skin and other tissues. Over the past 4 decades, the incidence of melanoma has increased more rapidly than that of any other malignancy in the United States. No current treatments substantially enhance patient survival once metastasis has occurred. This review focuses on recent insights into melanoma genetics and new therapeutic approaches being developed based on these advances.

Entities: Disease Species

Mesh：

Substances：
ras Proteins

Year: 2005 PMID： 15841168 PMCID： PMC1070435 DOI： 10.1172/JCI24808

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

118 in total

1. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.

Authors: F Petronzelli; D Sollima; G Coppola; M E Martini-Neri; G Neri; M Genuardi
Journal: Genes Chromosomes Cancer Date: 2001-08 Impact factor: 5.006

2. Model predicting survival in stage I melanoma based on tumor progression.

Authors: W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506

3. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

Authors: Y Zhang; Y Xiong; W G Yarbrough
Journal: Cell Date: 1998-03-20 Impact factor: 41.582

4. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors: T Papp; M Jafari; D Schiffmann
Journal: J Cancer Res Clin Oncol Date: 1996 Impact factor: 4.553

5. Pten is essential for embryonic development and tumour suppression.

Authors: A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal: Nat Genet Date: 1998-08 Impact factor: 38.330

6. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Authors: T Kamijo; J D Weber; G Zambetti; F Zindy; M F Roussel; C J Sherr
Journal: Proc Natl Acad Sci U S A Date: 1998-07-07 Impact factor: 11.205

7. Mutations of the BRAF gene in benign and malignant melanocytic lesions.

Authors: Amir S Yazdi; Gabriele Palmedo; Michael J Flaig; Ursula Puchta; Andrea Reckwerth; Arno Rütten; Thomas Mentzel; Heino Hügel; Markus Hantschke; Monika-Hildegard Schmid-Wendtner; Heinz Kutzner; Christian A Sander
Journal: J Invest Dermatol Date: 2003-11 Impact factor: 8.551

8. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo.

Authors: Norman Edward Sharpless; Karuppiah Kannan; Jin Xu; Marcus Wolfram Bosenberg; Lynda Chin
Journal: Oncogene Date: 2003-08-07 Impact factor: 9.867

9. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.

Authors: S F Zerp; A van Elsas; L T Peltenburg; P I Schrier
Journal: Br J Cancer Date: 1999-02 Impact factor: 7.640

10. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312

53 in total

Review 1. Oncogenic mutations of PIK3CA in human cancers.

Authors: Yardena Samuels; Todd Waldman
Journal: Curr Top Microbiol Immunol Date: 2010 Impact factor: 4.291

Review 2. Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors: József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal: Clin Exp Metastasis Date: 2010-02-24 Impact factor: 5.150

Review 3. [The role of ultraviolet irradiation in malignant melanoma].

Authors: C Berking
Journal: Hautarzt Date: 2005-07 Impact factor: 0.751

4. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.

Authors: Joel Pinczewski; Andrzej Slominski
Journal: Exp Dermatol Date: 2010-10 Impact factor: 3.960

5. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.

Authors: Damia Tormo; Aleix Ferrer; Evelyn Gaffal; Jörg Wenzel; Etiena Basner-Tschakarjan; Julia Steitz; Lukas C Heukamp; Ines Gütgemann; Reinhard Buettner; Marcos Malumbres; Mariano Barbacid; Glenn Merlino; Thomas Tüting
Journal: Am J Pathol Date: 2006-08 Impact factor: 4.307

6. NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.

Authors: Takeshi Namiki; Tomonori Yaguchi; Kenta Nakamura; Julio C Valencia; Sergio G Coelho; Lanlan Yin; Masakazu Kawaguchi; Wilfred D Vieira; Yasuhiko Kaneko; Atsushi Tanemura; Ichiro Katayama; Hiroo Yokozeki; Yutaka Kawakami; Vincent J Hearing
Journal: Cancer Res Date: 2015-04-01 Impact factor: 12.701